A funding boost of more than £78 million will help UCL scientists working to develop a potential treatment for motor neurone disease, for which there is currently no cure and which affects 5,000 ...

Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Clene (CLNN) to $83 from $86 and keeps a Buy rating on the shares.

Water, a molecule essential for life, has unusual properties—known as anomalies—that define its behavior. However, there are ...

Zac Brown Band's John Driskell Hopkins is turning his battle with ALS into a mission to help others: "When you're given a ...

Restaurateur Al Biernat passed away on Wednesday, November 13, after being diagnosed with amyotrophic lateral sclerosis, also ...

The National Institute of Aging awarded a $7.3 million research grant for the study of NU-9 as a treatment for ...

Amyotrophic Lateral Sclerosis Disease Program (PMN267) PMN267 is a humanized IgG1 antibody directed against toxic misfolded TDP-43 as a potential therapeutic target for amyotrophic lateral sclerosis ...

ALS is a neurodegenerative disease that progressively paralyzes individuals as the brain loses the ability to communicate with the muscles. People living with ALS often experience a swift decline in ...

The Oak Ridge Boys are on their “American Made” farewell tour and the group seems sincere about saying goodbye to the ...

She's spent many hours doing research and speaking with other caregivers to find her way to resources designed to help ...

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis.

In the rapidly evolving field of neuroimaging, the convergence of engineering advancements and medical expertise is reshaping our approach to understanding and treating neurological disorders. This ...